Annual report pursuant to Section 13 and 15(d)

Related Party Matters (Details)

v3.24.1
Related Party Matters (Details)
12 Months Ended
Mar. 01, 2023
USD ($)
May 18, 2022
USD ($)
shares
Mar. 01, 2022
USD ($)
Feb. 28, 2022
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
agreement
Related Party Transaction [Line Items]              
Related party transaction, compensation agreement, termination advance notice, duration       15 days      
Dr. Avtar Dhillon | Consulting Agreement              
Related Party Transaction [Line Items]              
Related party, fees incurred under agreement in the period         $ 35,087 $ 46,684  
Emerald Health Biotechnology Espana, S.L.U. | Collaborative Research Agreement              
Related Party Transaction [Line Items]              
Number of collaborative research agreements | agreement             2
Emerald Health Biotechnology Espana, S.L.U. | Collaborative Research Agreement | Emerald Health Research, Inc              
Related Party Transaction [Line Items]              
Ownership percentage             100.00%
Jim Heppell | Independent Contractor Services Agreement              
Related Party Transaction [Line Items]              
Monthly fee   $ 6,300          
Collaborative arrangement, rights and obligations, renewal term of agreement   1 year          
Related party transaction, increase in monthly fee   $ 16,600          
Granted (in shares) | shares   16,000          
Initial term of research agreement   1 year          
Termination terms, period following uncured breach   60 days          
Other current liabilities           75,503  
Related Party Transaction, Termination Payment $ 74,700            
Outstanding accounts payable           16,600  
Severance costs         0 139,615  
Brother Of CEO | Consulting Agreement              
Related Party Transaction [Line Items]              
Annual rate per hour       $ 73      
Independent Contractor Agreement | Dr. Avtar Dhillon              
Related Party Transaction [Line Items]              
Accrued expense under agreement           87,927  
Exclusive Sponsored Research Agreement | EHBE              
Related Party Transaction [Line Items]              
Related party transaction, accrued expenses         50,000 200,000  
Research and development         39,167 167,000  
ESRA Agreement, Screening Platform For Anteroposterior Ocular Diseases              
Related Party Transaction [Line Items]              
Other current liabilities         0 7,835  
Outstanding accounts payable         0 47,001  
ESRA Agreement, Screening Platform For Anteroposterior Ocular Diseases | EHBE              
Related Party Transaction [Line Items]              
Annual retainer amount     $ 190,500        
Outstanding accounts payable         0 50,000  
Consulting Agreement              
Related Party Transaction [Line Items]              
Other current liabilities         $ 0 $ 12,511